"Sanofi-Aventis (SNY), a pharmaceutical products company, is a buy based on our 'Benjamin Graham value' model," says John Reese who assesses stocks based on the investment criteria of numerous "legendary" investors.

The editor of Validea, explains, "Indeed, the stock earns a 100% score, meeting all of the investment criteria we review in for this value-oriented screen.

Continue reading Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model

Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model originally appeared on BloggingStocks on Fri, 01 Apr 2011 12:00:00 EST. Please see our terms for use of feeds.

Continue reading U.S. Stock Futures Up After Dell Reports Upbeat Earnings

U.S. Stock Futures Up After Dell Reports Upbeat Earnings originally appeared on BloggingStocks on Wed, 16 Feb 2011 08:30:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis Breast Cancer Drug Fails

Sanofi-Aventis Breast Cancer Drug Fails originally appeared on BloggingStocks on Fri, 28 Jan 2011 14:00:00 EST. Please see our terms for use of feeds.

The editor of Validea continues, "Sanofi-Aventis (SNY), which is involved in pharmaceuticals and human vaccines, earns a Guru Score of 100% based on the value investing strategy of Benjamin Graham.

"In its pharmaceutical activity, the company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Mon, 25 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

Continue reading Genzyme Lifted by Takeover Speculation

Genzyme Lifted by Takeover Speculation originally appeared on BloggingStocks on Thu, 29 Jul 2010 13:30:00 EST. Please see our terms for use of feeds.

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

Continue reading Goldman Sachs Targets Allergan as Takeover Candidate

Goldman Sachs Targets Allergan as Takeover Candidate originally appeared on BloggingStocks on Tue, 13 Jul 2010 13:30:00 EST. Please see our terms for use of feeds.

It appears that U.S.-based drug makers and cigarette companies caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot Friday:

Continue reading Allergan, BJ's Wholesale and Others Heating Up in Google

Allergan, BJ's Wholesale and Others Heating Up in Google originally appeared on BloggingStocks on Fri, 02 Jul 2010 16:30:00 EST. Please see our terms for use of feeds.

"Sanofi-Aventis (SNY) is a pharmaceutical group engaged in the research, development, manufacture and marketing of health care products; the stock gets a 100% score in meeting the criteria for our investment screen based on d value investing criteria used by the legendary Benjamin Graham," says John Reese.

The editor of Validea newsletter explains, "The company's business includes two main activities: pharmaceuticals and human vaccines. The company is also present in animal health products.

"In its pharmaceutical activity, the Company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Wed, 30 Jun 2010 10:15:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis Dips on Eloxatin Patent Settlements

Sanofi-Aventis Dips on Eloxatin Patent Settlements originally appeared on BloggingStocks on Tue, 06 Apr 2010 13:20:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis (SNY): A Growth and Value Play

Sanofi-Aventis (SNY): A Growth and Value Play originally appeared on BloggingStocks on Mon, 05 Apr 2010 12:00:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Our top stock pick for 2010 is ImmunoGen (IMGN)," says biotech specialist John McCamant.

In his The Medical Technology Stock Letter, he explains, "The company's potent cancer-cell killing antibodies were developed for targeted delivery to tumor cells."

Continue reading Top Picks for 2010: ImmunoGen (IMGN)

Top Picks for 2010: ImmunoGen (IMGN) originally appeared on BloggingStocks on Fri, 25 Dec 2009 14:00:00 EST. Please see our terms for use of feeds.

From TheStreet.com Network

• Dollar Store: Early Volume Plays
• Dollar Could Steer Stocks in Coming Week

Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts

Cramer on BloggingStocks: Sanofi has lots of upside catalysts originally appeared on BloggingStocks on Mon, 23 Nov 2009 10:00:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis (SNY) gains on UNH swine flu assurances

Sanofi-Aventis (SNY) gains on UNH swine flu assurances originally appeared on BloggingStocks on Fri, 21 Aug 2009 13:40:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Jefferies upgraded Buffalo Wild Wings (NASDAQ: BWLD) to Buy from Hold on valuation with the stock down 65% in two months as they believe the company has a "best-in-class fundamental story." The firm lowered its target to $25 from $30.
• Morgan Stanley upgraded Sanofi-Aventis (NYSE: SNY) to Overweight from Equal Weight on valuation and believes near-term cost reductions could provide a positive catalyst.
• Citigroup upgraded New York Times (NYSE: NYT) to Hold from Sell and lowered its target to $5.50 from $7 on valuation and believes the dividend cut will boost the company's liquidity.
• Pantry (NASDAQL PTRY) was upgraded to Outperform from Market Perform at Friedman Billings.
• LECG Corp (NASDAQ: XPRT) was raised to Buy from Neutral at UBS.
• Thomson Reuters (NYSE: TRI) was upgraded at RBC Capital to Outperform from Sector Perform.

• Jefferies downgraded Suntech (NYSE: STP) to Hold from Buy and lowered its target to $6 from $25 as they believe concerns about a convert refinancing in February 2010 will continue to weigh on the stock.
• Credit Suisse cut Ericsson (NASDAQ: ERIC) to Underperform from Outperform due to expectations for a decline in wireless infrastructure spending.
• ING downgraded shares of Rio Tinto (NYSE: RTP) to Hold from Buy as they believe it will be challenging for the company to execute asset sales planned at reducing debt in the current environment.

Continue reading Analyst calls: BWLD, SNY, NYT, STP, ERIC, RTP, KTOS, ZGEN

Analyst calls: BWLD, SNY, NYT, STP, ERIC, RTP, KTOS, ZGEN originally appeared on BloggingStocks on Mon, 24 Nov 2008 10:57:00 EST. Please see our terms for use of feeds.

For a bullish hedged play on this stock, I would consider a December bull-put credit spread below the $32.50 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 19.0% return in just three and a half months as long as SNY is above $32.50 at December expiration. Sanofi would have to fall by more than 8% before we would start to lose money. Learn more about this type of trade here.

Continue reading Sanofi-Aventis (SNY) flies high on new CEO

Sanofi-Aventis (SNY) flies high on new CEO originally appeared on BloggingStocks on Wed, 10 Sep 2008 01:15:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Oppenheimer initiated SuccessFactors Inc (NASDAQ: SFSF) with an Outperform rating and $15 target. The firm believes the company's double-digit revenue growth will continue as its differentiated HCM solutions gain broad-based adoption. Deutsche Bank believes the company has a strong opportunity to build a highly profitable business as it broadens its footprint, and started shares with a Buy rating and $15 target.
• Deutsche Bank also reinstated coverage of Taleo Corporation (NASDAQ: TLEO) with a Buy rating and $35 target. The firm believes the Vurv acquisition will create significant accretion in 2009 and that investors should take advantage of the recent share weakness.
• Oppenheimer assumed coverage of Penn National Gaming Inc (NASDAQ: PENN) with an Outperform rating and believes the termination of Penn's acquisition by Fortress Investment and Centerbridge will be catalysts for the stock, as they think it provides the company with financial flexibility. In addition, the firm believes Penn's management team has historically made prudent capital decisions.

• Petrobras Brasileiro SA (NYSE: PBR) was initiated with a Buy rating and $92 target at Goldman.
• Cowen resumed coverage of LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating.
• Sanofi-Aventis SA (NYSE: SNY) was started at ING with a Hold rating.

Analyst initiations: SFSF, TLEO, SNY and PENN originally appeared on BloggingStocks on Mon, 07 Jul 2008 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Sanofi-Aventis (SNY) plunges on Plavix threat in Europe

Sanofi-Aventis (SNY) plunges on Plavix threat in Europe originally appeared on BloggingStocks on Fri, 09 May 2008 13:12:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Once thought to be extremely safe, action rate securities have proved difficult to sell in this credit crisis. Tech companies are big holders of them and are taking charges left and right, including MetroPCS Communications Inc (NYSE: PCS), Palm Inc (NASDAQ: PALM) and Earthlink Inc (NASDAQ: ELNK), according to the Wall Street Journal.
• Electronic Arts Inc (NASDAQ: ERTS) is again urging Take-Two Interactive Software Inc (NASDAQ: TTWO) to negotiate after it recommended that its stockholders not sell any of its shares to EA and help its $2B takeover bid, the Financial Times reported.

• NYSE Euronext Inc (NYSE: NYX) will look to increase its stakes in India's National Stock Exchange and the country's Multi Commodity Exchange, the Business Standard reported, once foreign ownership rules are eased. NYSE Euronext also intends to partner with the two Indian exchanges in order to help them develop their business.

• Business Week reported that Brian Marckx of Zacks Investment Research said Bristol Myers Squibb Company (NYSE: BMY) may be an attractive takeover candidate for a larger pharma such as Pfizer Inc (NYSE: PFE) or France's Sanofi-Aventis SA (NYSE: SNY), both of which have been partners with Bristol on some of its products.

Newspaper wrap-up: Tech firm profits hurt by auction rate securities originally appeared on BloggingStocks on Fri, 28 Mar 2008 08:00:00 EST. Please see our terms for use of feeds.

Monday October 22

• Halliburton Company (NYSE: HAL) to report Q3 earnings; conference call at 10am
• Apple Inc (NASDAQ: AAPL) to report Q3 earnings; conference call at 5pm
• Texas Instruments Incorporated (NYSE: TXN) to report Q3 earnings; conference call at 5:30pm

• Lockheed Martin Corporation (NYSE: LMT) to report Q3 earnings; conference call at 11am
• Amazon.com Inc (NASDAQ: AMZN) to report Q3 earnings; conference call at 5pm

• Merrill Lynch & Co Inc (NYSE: MER) to report Q3 earnings; conference call at 10am
• The Boeing Company (NYSE: BA) to report Q3 earnings; conference call at 10:30am

• XM Satellite Radio Holdings Inc (NASDAQ: XMSR) to report Q3 earnings; conference call at 10am
• Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT) to report Q3 earnings; conference call at 10:30am

• Countrywide Financial Corporation (NYSE: CFC) to report Q3 earnings; conference call at 12pm
• PDUFA date for Adams Respiratory Therapeutics Inc's (NASDAQ: ARXT) Guaifenesin, a prescription cough treatment
• PDUFA date for Sanofi-Aventis SA's (NYSE: SNY) Taxotere for induction therapy of locally advanced head and neck cancer prior to chemoradiotherapy and surgery

Market highlights for next week: AAPL, AMZN, MER, CFC to report Q3 originally appeared on BloggingStocks on Fri, 19 Oct 2007 16:00:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Societe Generale upgraded shares of Sanofi-Aventis (NYSE: SNY) to Buy from Hold as they believe pipeline maturation over the next 12 months can drive the stock higher.
  
• Piper upgraded shares of Lifecell (NASDAQ: LIFC) to Outperform from Market Perform after their recent survey indicated that AlloDerm remains the leading biologic hernia mesh on the market and competition is making little headway.
  
• JP Morgan upgraded Mylan Labs (NYSE: MYL), Panera Bread (NASDAQ: PNRA) and Norsk Hydro (NYSE: NHY) to Overweight from Neutral. The firm upgraded Mylan based on its position in the global generics market and above-average growth; Panera was upgraded on valuation, as they believe the recent operating risk is now behind the company; Norsk Hydro was upgraded, as they believe the value of the company's aluminum assets are higher than the current share price suggests.

• HSBC upgraded Ride Aid (NYSE: RAD) to Neutral from Underweight.
  
• UBS upgraded Standard Pacific (NYSE: SPF) and Ciena (NASDAQ: CIEN) to Neutral from Sell and Sherwin-Williams (NYSE: SHW) to Buy from Neutral.
  
• Goldman added Cytec Industries (NYSE: CYT) to its Conviction Buy List.

Analyst upgrades: SNY, LIFC, MYL, PNRA and NHY originally appeared on BloggingStocks on Thu, 04 Oct 2007 10:45:00 EST. Please see our terms for use of feeds.